Xintela AB is a biomedical company. It engages in the business of developing medical products in stem cell therapy and targeted cancer therapy based on the cell surface marker integrin a10ß1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The company was founded by Evy Lundgren-Åkerlund and Rickard Mosell in 2009 and is headquartered in Lund, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company